摘要
Abstract
Objective To analyze the effect of carrilizumab combined with chemotherapy in the treatment of advanced esophageal cancer and its influence on quality of life.Methods 80 cases of patients with advanced esophageal cancer who were admitted to our hospital from August 2020 to August 2023 were selected by convenient sampling method and divided into groups based on computer random number table method.The treatment regimen was chemotherapy for 40 patients in the control group and carrilizumab combined chemotherapy for 40 patients in the study group.The clinical efficacy,serum tumor markers,safety and quality of life of the two groups were compared.Results After treatment,in the study group,the total effective rate was 70.00%,and it was 45.00%in the control group,the difference was statistically significant(P<0.05).In the study group,the serum expressions of SCC-Ag,CEA,HMGB1 and CA125 were significantly lower than the control group,the difference was statistically significant(P<0.05).In the study group,the incidence of adverse reactions was 35.00%and 27.50%in the control group,with no statistical difference between the two groups(P>0.05).In the study group,the FACT-G score was(79.05±17.17)points,and that of the control group was(67.65±17.42)points,which was higher in the study group,the difference was statistically significant(P<0.05).Conclusion Raylizumab combined with chemotherapy in the treatment of advanced esophageal cancer can achieve satisfactory results and improve clinical efficacy.Meanwhile,the expression of serum tumor markers was down-regulated.Promote the quality of life of patients to further improve,and safe and reliable.关键词
卡瑞利珠单抗/化疗/晚期食管癌/生存质量/安全性Key words
Carrilizumab/chemotherapy/advanced esophageal cancer/quality of life/security分类
临床医学
